Founded in 2011, Alloy Therapeutics operates in biotech. Investors last valued the company at $1B. Its shares do not trade on a public exchange.
1 valuation. The latest, $1B post-money, was set by the Series E in Apr 2026.
8VCLEADMMubadala CapitalLEADFFelicisLEADPPeter ThielLEADJJIC Venture Growth InvestmentsEEcho CapitalPPresight CapitalTThiel Capital
Founders FundAAlexandria Venture Investments8VCMubadala CapitalFelicisPeter ThielAlloy Therapeutics provides antibody discovery and biologics discovery tools and services, giving academic labs, small and medium biotech companies, and large pharmaceutical firms shared, non-exclusive access to technology for developing monoclonal antibodies, bispecific and multispecific antibodies, and TCR mimics. In April 2025, it entered a multi-year collaboration with Pfizer to build a new antibody discovery platform together.
Founded in 2011 and based in the United States, the company also operates as Alloy Therapeutics Switzerland AG and describes itself as building a fully integrated product development organization for the drug discovery community.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Alloy Therapeutics.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Alloy Therapeutics availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Alloy Therapeutics included.
The routes section explains what is realistically available for a company at this stage.
No. Alloy Therapeutics is a private company; its shares do not trade on a public exchange.
The last valuation is $1B.
Lead investors for each round are in the funding timeline.
The closest biotech peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
